CymaBay Therapeutics

443 posts

CymaBay Therapeutics banner
CymaBay Therapeutics

CymaBay Therapeutics

@CymaBay

We are a global clinical-stage biopharma company developing solutions for patients with liver diseases.

newark, ca Beigetreten Haziran 2019
192 Folgt423 Follower
Angehefteter Tweet
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
As CymaBay is now part of @GileadSciences, this account is no longer active. We look forward to advancing our shared mission. Thank you for your support.
CymaBay Therapeutics tweet media
English
0
0
2
412
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
Primary biliary cholangitis (PBC) is a rare, chronic, autoimmune liver disease that progressively destroys the liver’s bile ducts. Learn more about PBC here: bit.ly/3KRMfjT
English
0
1
2
252
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
We are proud to present our latest research in primary biliary cholangitis at #EASLCongress 2024 as part of Gilead’s research across liver diseases. Learn more at: bit.ly/3UMVUg6
Gilead Sciences@GileadSciences

#GileadNews: We’ll share the latest data from our liver disease franchise at #EASLCongress, underlining our drive for life-changing science to create healthier futures for people living with liver disease. Read more: gilead.inc/4ayTiIB

English
0
0
1
155
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
Last week, we welcomed some new recruits to our team on #BringYourChildToWorkDay. It was a day full of fun activities and #STEM experiments to inspire us all. They did a great job in their final presentation!
CymaBay Therapeutics tweet media
English
0
0
0
102
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
Today we become a wholly owned subsidiary of @GileadSciences. We’ve always been dedicated to advancing life-changing treatments, and together we’ll be able to further our commitment to improve the lives of people with liver disease. bit.ly/3TKiEOz
CymaBay Therapeutics tweet media
English
0
1
1
181
CymaBay Therapeutics
CymaBay Therapeutics@CymaBay·
We are pleased to be onsite with the European liver community at the Paris Hepatology Conference discussing the impact of Primary Biliary Cholangitis (PBC). For more information, visit: bit.ly/49R2991 #HybridPHC2024
CymaBay Therapeutics tweet media
English
1
0
1
155